# Indivior Pharmaceuticals, Inc.: financial statements, quarterly

INDV · Nasdaq · CIK 1625297 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/indv.md) · [Financials](/companies/indv/financials.md) · [Filings](/companies/indv/filings.md) · [Insiders](/companies/indv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/indv/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [284](/filings/0001625297-25-000030.md) | [299](/filings/0001625297-25-000050.md) | [307](/filings/0001628280-25-047530.md) | [299 d](/filings/0001628280-26-012237.md) | [266](/filings/0001628280-26-028850.md) | [302](/filings/0001628280-26-051895.md) | [314](/filings/0001628280-26-068013.md) | [358 d](/filings/0001628280-26-012237.md) | [317](/filings/0001628280-26-028850.md) | [343](/filings/0001628280-26-051895.md) | [356](/filings/0001628280-26-068013.md) |
| Cost of revenue | $m | [38.0](/filings/0001625297-25-000030.md) | [79.0](/filings/0001625297-25-000050.md) | [66.0](/filings/0001628280-25-047530.md) | [48.0 d](/filings/0001628280-26-012237.md) | [44.0](/filings/0001628280-26-028850.md) | [52.0](/filings/0001628280-26-051895.md) | [83.0](/filings/0001628280-26-068013.md) | [67.0 d](/filings/0001628280-26-012237.md) | [40.0](/filings/0001628280-26-028850.md) | [50.0](/filings/0001628280-26-051895.md) | [51.0](/filings/0001628280-26-068013.md) |
| Gross profit | $m | [246](/filings/0001625297-25-000030.md) | [220](/filings/0001625297-25-000050.md) | [241](/filings/0001628280-25-047530.md) | [250 d](/filings/0001628280-26-012237.md) | [221](/filings/0001628280-26-028850.md) | [250](/filings/0001628280-26-051895.md) | [230](/filings/0001628280-26-068013.md) | [292 d](/filings/0001628280-26-012237.md) | [277](/filings/0001628280-26-028850.md) | [294](/filings/0001628280-26-051895.md) | [305](/filings/0001628280-26-068013.md) |
| Selling, general and administrative | $m | [143](/filings/0001628280-26-012237.md) | [152](/filings/0001628280-26-012237.md) | [142](/filings/0001628280-26-012237.md) | [175](/filings/0001628280-26-012237.md) | [133](/filings/0001628280-26-028850.md) | [158](/filings/0001628280-26-051895.md) | [154](/filings/0001628280-26-068013.md) | [189 d](/filings/0001628280-26-012237.md) | [124](/filings/0001628280-26-028850.md) | [122](/filings/0001628280-26-051895.md) | [119](/filings/0001628280-26-068013.md) |
| Operating income | $m | [75.0](/filings/0001628280-26-012237.md) | [(118)](/filings/0001628280-26-012237.md) | [35.0](/filings/0001628280-26-012237.md) | [46.0](/filings/0001628280-26-012237.md) | [66.0](/filings/0001628280-26-028850.md) | [72.0](/filings/0001628280-26-051895.md) | [43.0](/filings/0001628280-26-068013.md) | [81.0 d](/filings/0001628280-26-012237.md) | [137](/filings/0001628280-26-028850.md) | [160](/filings/0001628280-26-051895.md) | [180](/filings/0001628280-26-068013.md) |
| Interest expense | $m | [9.0](/filings/0001625297-25-000030.md) | [9.0](/filings/0001625297-25-000050.md) | [11.0](/filings/0001628280-25-047530.md) | [13.0 d](/filings/0001628280-26-012237.md) | [12.0](/filings/0001628280-26-028850.md) | [15.0](/filings/0001628280-26-051895.md) | [12.0](/filings/0001628280-26-068013.md) | [6.0 d](/filings/0001628280-26-012237.md) | [7.0](/filings/0001628280-26-028850.md) | [2.0](/filings/0001628280-26-051895.md) | [2.0](/filings/0001628280-26-068013.md) |
| Income tax | $m | [11.0](/filings/0001628280-26-012237.md) | [(23.0)](/filings/0001628280-26-012237.md) | [8.0](/filings/0001628280-26-012237.md) | [17.0](/filings/0001628280-26-012237.md) | [11.0](/filings/0001628280-26-028850.md) | [44.0](/filings/0001628280-26-051895.md) | [(5.0)](/filings/0001628280-26-068013.md) | [(21.0) d](/filings/0001628280-26-012237.md) | [26.0](/filings/0001628280-26-028850.md) | [38.0](/filings/0001628280-26-051895.md) | [45.0](/filings/0001628280-26-068013.md) |
| Net income | $m | [61.0](/filings/0001628280-26-012237.md) | [(97.0)](/filings/0001628280-26-012237.md) | [22.0](/filings/0001628280-26-012237.md) | [21.0](/filings/0001628280-26-012237.md) | [47.0](/filings/0001628280-26-068013.md) | [18.0](/filings/0001628280-26-068013.md) | [42.0](/filings/0001628280-26-068013.md) | [102 d](/filings/0001628280-26-012237.md) | [89.0](/filings/0001628280-26-068013.md) | [122](/filings/0001628280-26-068013.md) | [137](/filings/0001628280-26-068013.md) |
| Diluted EPS | $ per share | [0.45](/filings/0001625297-25-000030.md) | [(0.72)](/filings/0001625297-25-000050.md) | [0.16](/filings/0001628280-25-047530.md) | not reported | [0.38](/filings/0001628280-26-028850.md) | [0.14](/filings/0001628280-26-051895.md) | [0.33](/filings/0001628280-26-068013.md) | not reported | [0.69](/filings/0001628280-26-028850.md) | [0.98](/filings/0001628280-26-051895.md) | [1.12](/filings/0001628280-26-068013.md) |
| Basic EPS | $ per share | [0.45](/filings/0001625297-25-000030.md) | [(0.72)](/filings/0001625297-25-000050.md) | [0.16](/filings/0001628280-25-047530.md) | not reported | [0.38](/filings/0001628280-26-028850.md) | [0.15](/filings/0001628280-26-051895.md) | [0.34](/filings/0001628280-26-068013.md) | not reported | [0.71](/filings/0001628280-26-028850.md) | [1.02](/filings/0001628280-26-051895.md) | [1.16](/filings/0001628280-26-068013.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [316](/filings/0001625297-25-000016.md) | not reported | not reported | not reported | [319](/filings/0001628280-26-012237.md) | [372](/filings/0001625297-25-000030.md) | [510](/filings/0001625297-25-000050.md) | [445](/filings/0001628280-25-047530.md) | [195](/filings/0001628280-26-068013.md) | [175](/filings/0001628280-26-028850.md) | [222](/filings/0001628280-26-051895.md) | [305](/filings/0001628280-26-068013.md) |
| Current assets | $m | [1,257](/filings/0001628280-26-012237.md) | not reported | not reported | not reported | [827](/filings/0001628280-26-012237.md) | [883](/filings/0001625297-25-000030.md) | [951](/filings/0001625297-25-000050.md) | [922](/filings/0001628280-25-047530.md) | [652](/filings/0001628280-26-068013.md) | [667](/filings/0001628280-26-028850.md) | [725](/filings/0001628280-26-051895.md) | [800](/filings/0001628280-26-068013.md) |
| Total assets | $m | [1,758](/filings/0001628280-26-012237.md) | not reported | not reported | not reported | [1,316](/filings/0001628280-26-012237.md) | [1,375](/filings/0001625297-25-000030.md) | [1,452](/filings/0001625297-25-000050.md) | [1,416](/filings/0001628280-25-047530.md) | [1,201](/filings/0001628280-26-068013.md) | [1,197](/filings/0001628280-26-028850.md) | [1,233](/filings/0001628280-26-051895.md) | [1,332](/filings/0001628280-26-068013.md) |
| Current liabilities | $m | [1,281](/filings/0001628280-26-012237.md) | not reported | not reported | not reported | [924](/filings/0001628280-26-012237.md) | [1,005](/filings/0001625297-25-000030.md) | [1,056](/filings/0001625297-25-000050.md) | [965](/filings/0001628280-25-047530.md) | [914](/filings/0001628280-26-068013.md) | [779](/filings/0001628280-26-028850.md) | [868](/filings/0001628280-26-051895.md) | [1,301](/filings/0001628280-26-068013.md) |
| Total liabilities | $m | [1,942](/filings/0001628280-26-012237.md) | not reported | not reported | not reported | [1,652](/filings/0001628280-26-012237.md) | [1,660](/filings/0001625297-25-000030.md) | [1,709](/filings/0001625297-25-000050.md) | [1,623](/filings/0001628280-25-047530.md) | [1,300](/filings/0001628280-26-068013.md) | [1,341](/filings/0001628280-26-028850.md) | [1,441](/filings/0001628280-26-051895.md) | [1,392](/filings/0001628280-26-068013.md) |
| Long-term debt | $m | [237](/filings/0001625297-25-000016.md) | not reported | not reported | not reported | [315](/filings/0001628280-26-012237.md) | [311](/filings/0001625297-25-000030.md) | [308](/filings/0001625297-25-000050.md) | [304](/filings/0001628280-25-047530.md) | [290](/filings/0001628280-26-068013.md) | [486](/filings/0001628280-26-028850.md) | [487](/filings/0001628280-26-051895.md) | [0.0](/filings/0001628280-26-068013.md) |
| Current portion of debt | $m | [3.0](/filings/0001625297-25-000016.md) | not reported | not reported | not reported | [18.0](/filings/0001628280-26-012237.md) | [18.0](/filings/0001625297-25-000030.md) | [18.0](/filings/0001625297-25-000050.md) | [18.0](/filings/0001628280-25-047530.md) | [29.0](/filings/0001628280-26-068013.md) | [0.0](/filings/0001628280-26-028850.md) | [0.0](/filings/0001628280-26-051895.md) | [488](/filings/0001628280-26-068013.md) |
| Shareholders' equity | $m | [(184)](/filings/0001628280-26-012237.md) | [(161)](/filings/0001628280-25-047530.md) | [(281)](/filings/0001628280-25-047530.md) | [(310)](/filings/0001628280-25-047530.md) | [(337)](/filings/0001628280-26-068013.md) | [(285)](/filings/0001628280-26-068013.md) | [(257)](/filings/0001628280-26-068013.md) | [(207)](/filings/0001628280-26-068013.md) | [(98.0)](/filings/0001628280-26-068013.md) | [(144)](/filings/0001628280-26-068013.md) | [(208)](/filings/0001628280-26-068013.md) | [(60.0)](/filings/0001628280-26-068013.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(37.0)](/filings/0001625297-25-000030.md) | [88.0 d](/filings/0001625297-25-000050.md) | [2.0 d](/filings/0001628280-25-047530.md) | [(17.0) d](/filings/0001628280-26-012237.md) | [75.0](/filings/0001628280-26-028850.md) | [158 d](/filings/0001628280-26-051895.md) | [(39.0) d](/filings/0001628280-26-068013.md) | [(221) d](/filings/0001628280-26-012237.md) | [(9.0)](/filings/0001628280-26-028850.md) | [229 d](/filings/0001628280-26-051895.md) | [97.0 d](/filings/0001628280-26-068013.md) |
| Capital expenditure | $m | [2.0](/filings/0001625297-25-000030.md) | [4.0 d](/filings/0001625297-25-000050.md) | [7.0 d](/filings/0001628280-25-047530.md) | [16.0 d](/filings/0001628280-26-012237.md) | [5.0](/filings/0001628280-26-028850.md) | [17.0 d](/filings/0001628280-26-051895.md) | [20.0 d](/filings/0001628280-26-068013.md) | [24.0 d](/filings/0001628280-26-012237.md) | [20.0](/filings/0001628280-26-028850.md) | [7.0 d](/filings/0001628280-26-051895.md) | [14.0 d](/filings/0001628280-26-068013.md) |
| Share repurchases | $m | [36.0](/filings/0001625297-25-000030.md) | [35.0 d](/filings/0001625297-25-000050.md) | [52.0 d](/filings/0001628280-25-047530.md) | [50.0 d](/filings/0001628280-26-012237.md) | [11.0](/filings/0001628280-26-028850.md) | [0.0 d](/filings/0001628280-26-051895.md) | [0.0 d](/filings/0001628280-26-068013.md) | [0.0 d](/filings/0001628280-26-012237.md) | [125](/filings/0001628280-26-068013.md) | [177 d](/filings/0001628280-26-051895.md) | [0.0 d](/filings/0001628280-26-068013.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [137](/filings/0001625297-25-000030.md) | [135](/filings/0001625297-25-000050.md) | [133](/filings/0001628280-25-047530.md) | [125](/filings/0001628280-26-028850.md) | [126](/filings/0001628280-26-051895.md) | [129](/filings/0001628280-26-068013.md) | [129](/filings/0001628280-26-028850.md) | [124](/filings/0001628280-26-051895.md) | [122](/filings/0001628280-26-068013.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 118,035,272 at 2026-10-09, from the cover of the [10-Q filed 2026-10-29](/filings/0001628280-26-068013.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 08:21 ET. No prices; not investment advice.